Toxicological insights and safety considerations of vorasidenib in grade 2 astrocytoma and oligodendroglioma-research letter
{{output}}
Vorasidenib, a dual inhibitor of isocitrate dehydrogenase 1 and 2 (IDH1/2), has shown promise as a therapeutic agent following its recent FDA approval for the treatment of grade 2 astrocytomas and oligodendrogliomas harboring IDH mutations in patients 12 years... ...
